Their U.S. partner is experienced in commercializing antibiotics. Cidara Therapeutics (NASDAQ:CDTX) is a microcap (~$115 million market cap) biotechnology company developing long-acting therapeutics. They received a $20 million milestone payment from partner Melinta Therapeutics following the U.S. Food and Drug Administration (FDA) approval of REZZAYO for the treatment of candidemia…Read More
Buy Cidara Therapeutics For Data Readout And European Foothold NASDAQCDTX
